AB Science (XPAR:AB) Institutional Ownership : 1.18% (As of Jun. 01, 2024)

View and export this data going back to 2010. Start your Free Trial

What is AB Science Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AB Science's institutional ownership is 1.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AB Science's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AB Science's Float Percentage Of Total Shares Outstanding is 0.00%.

AB Science Institutional Ownership Historical Data

The historical data trend for AB Science's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AB Science Institutional Ownership Chart

AB Science Historical Data

The historical data trend for AB Science can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	2.45	1.89	1.28	1.34	1.43	1.51	1.36	1.20	1.18	1.18

AB Science Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

AB Science (XPAR:AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AB Science (XPAR:AB) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ABSCF:USA

Address

3, Avenue George V, Paris, FRA, 75008

Website

https://www.ab-science.com

AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.